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Fine-tuned Orchestration of Cell Adhesion and Migration
Cell adhesion and migration is a central process in the development and maintenance of
multicellular organisms (Friedl et al., 2012). Tissue formation during embryonic development,
wound healing, and immune responses all require the fine-tuned, orchestrated movement of cells.
In this regard, recent cutting-edge studies have elucidated how cell adhesion and migration achieve
three-dimensional collective cell movement (Rørth, 2012; Matsui et al., 2015). That is, collective cell
movement uses a mechanical guidance system where each cell in the cell groups individually but
coordinately guides the global motion of the cell groups. This mechanism is involved in a variety of
biological reactions such as embryonic morphogenesis, organogenesis, immune reactions, and/or
carcinogenesis (Friedl and Gilmour, 2009). In this review article, we will particularly pick up
immune reactions in central nervous system (CNS) and CNS tumors to look into the fine-tuned
mechanisms how cell adhesion and migration are involved in physiological condition as well as
pathological conditions.
Significance of Cell Adhesion in CNS/CNS Tumor Immunology
In the past, the CNS has been characterized as an immunologically privileged site. Nowadays,
however, immune reactions are known to occur in the CNS (Ousman and Kubes, 2012). In
particular, regarding immune cell trafficking to the brain, the mechanisms how leukocytes
translocate from high velocity circulation into the brain parenchyma is explained as follows: (1)
tethering/rolling, (2) activation, (3) adhesion, and (4) transmigration (Engelhardt, 2008). Briefly,
leukocytes slow down on endothelial cells by selectin-mediated interactions expressed on both of
the cell types. Then, at a reduced velocity, the leukocytes sense chemokines on the endothelial
cells and become activated through G-protein signaling to upregulate integrins (Fujita et al.,
2009). Finally, with this tight interaction in place, leukocytes transmigrate into the parenchyma
to function. In the following section, we discuss major adhesion molecules that are relevant to this
process.
ICAM1-LFA1 Interaction for T Lymphocytes
ICAM1 (Intercellular Adhesion Molecule 1), which is also known as CD54, is a cell surface
glycoprotein that is typically expressed on endothelial cells as well as distinct subsets of leukocytes
(Rothlein et al., 1986). ICAM1 is a ligand for LFA1 (Lymphocyte Function-Associated molecule 1),
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a receptor primarily expressed on leukocytes. As mentioned
above, when leukocytes slow down via interactions between LFA1
on leukocytes and ICAM1 on endothelial cells, the leukocytes
become activated by chemokine signals (we will discuss later)
and further upregulate the expression levels of the integrins. In
particular, the interaction between ICAM1 and LFA1 is a crucial
step in the generation of tumor-specific cytotoxic T lymphocytes
(CTLs) (Jenkinson et al., 2005). It is also required for the in
situ activation and the migration of the CTLs (Bachmann et al.,
1997). Moreover, ICAM1 has been shown to play a pivotal role
in physical and functional interaction between CNS tumors and
CTLs (Ueda et al., 2009). Therefore, malignant CNS tumor cells
reduce the expression levels of ICAM1 to achieve their tumor
immune escape (Dunn et al., 2007).
VCAM1-VLA4 Interaction for T Lymphocytes
VCAM1 (Vascular Cell Adhesion Molecule 1), which is also
known as CD106, mediates the adhesion of lymphocytes,
monocytes, eosinophils, and basophils to vascular endothelium
(Cybulsky et al., 1991). It also functions in leukocyte-endothelial
cell signal transduction. VCAM1 interacts with VLA4 (Very Late
Antigen-4 or integrin α4β1) (Lin and Castro, 1998).
Expression of tissue-specific homing molecules directs
antigen-experienced T lymphocytes to particular peripheral
tissues. It is therefore essential to gain understanding of
pivotal homing receptors that dictate CNS tumor-homing of
T lymphocytes. It has been shown that in vivo imprinting of
distinct homing phenotypes of T lymphocytes occurs in response
to tumor-expressing antigens in intracerebral, subcutaneous, and
intraperitoneal sites (Calzascia et al., 2005). In addition, CNS-
homing type-1 CTLs (Tc1; the most potent effector T cells)
but not its counterpart type-2 CTLs (Tc2) preferentially express
VLA4 (Sasaki et al., 2007; Zhu et al., 2007). As mentioned above,
ICAM1-LFA1 interaction enhances a stable interaction between
VCAM1 and VLA4, which allows the cells to migrate into brain
parenchyma (Sasaki et al., 2008).
CADM1-mediated Interaction for Dendritic Cells
(DCs)
CADM1 (Cell Adhesion Molecule 1) is an immunoglobulin
superfamily member that is expressed on neuron cells such as
superior cervical ganglions (Watabe et al., 2003). In addition,
a soluble form of CADM1 (sCADM1) can be generated as
an alternative splicing variant, which is involved in directional
neuron extension (Hagiyama et al., 2009). CADM1 has been
shown to interact with an intracytoplasmic protein DAL1 (Yageta
et al., 2002).
DCs are known to be antigen-presenting cells (APCs) of the
mammalian immune system; they act as messengers between
the innate and the adaptive immune systems (Palucka and
Banchereau, 2012). Their main function is to process antigen
material and present it on the cell surface to naive T lymphocytes
to activate them. Therefore, they decide how T lymphocytes
differentiate. Recent studies have shown that a certain subset
of DCs express CADM1 (Dutertre et al., 2014). In addition,
CADM1-postive and CADM1-negative subsets correspond to
type-1 DCs (which induces type-1 T lymphocytes such as
Tc1) and type-2 DCs, respectively. These data suggest that
CNS tumors may preferentially induce immunosuppressive
milieu by promoting CADM1-negative DCs in the tumor
microenvironment.
Significance of Cell Migration in CNS/CNS
Tumor Immunology
In turn, regarding the cell migration in CNS immunology, the
most important factors are chemokines because they act as a
chemoattractant to guide the migration of leukocytes directly
(Proudfoot, 2002). Chemokines are a family of cytokines and
classified into four main subfamilies: CXC, CC, CX3C, and
XC (Zlotnik and Yoshie, 2012). All of these proteins exert
their biological effects by interacting with G protein-linked
transmembrane receptors called chemokine receptors that are
selectively found on the surfaces of their target cells. Some
chemokines are involved in immune surveillance; they direct
lymphocytes to the lymph nodes so that the lymphocytes can
screen for invasion of pathogens by interacting with APCs
residing in these tissues. Some chemokines have roles in
development; they promote angiogenesis or guide cells to tissues
that provide specific signals critical for cellular maturation. Other
chemokines are inflammatory; they are released from a wide
variety of cells in response to bacterial infection. Inflammatory
chemokines function mainly as chemoattractants for leukocytes
to recruit them from the blood to sites of infection or tissue
damage. In the following sections, we discuss about the CNS
tumor-relevant immunology from a viewpoint of chemokines.
CCR7-CCL19/CCL21 Axis for DCs
CCR7 is a chemokine receptor that is expressed by various
subsets of leukocytes, and its ligands are CCL19 and CCL21
(Förster et al., 2008). These chemokines are constitutively
expressed and control cell movement during homeostasis. CCR7-
CCL19/21 chemokine axis is essentially involved in homing of
activated DCs to the lymph nodes. Within lymph nodes of the
systemic immune system, T lymphocytes establish close physical
contacts with DCs, which allows their antigen-specific activation
(Ganguly et al., 2013).
In contrast, in the CNS, a variety of cell populations
have been postulated as primary APCs: vascular endothelial
cells, smooth muscle cells, astrocytes, perivascular macrophages,
choroid plexus epithelial cells, neurons, and DCs (Dunn et al.,
2007). Presentation of CNS antigens by APCs can occur through
multiple mechanisms (Walker et al., 2003): (1) APC uptake
antigen within the CNS and migrate to lymph nodes to present
antigens; (2) antigen drains to lymph nodes where APCs take
them up to present; and (3) cells that express the antigen directly
drain to lymph nodes and present their own antigen (direct
presentation as opposed to cross presentation by DCs). In the
process of lymph node-homing of DCs, CCR7 appears to play a
central role in this process. Indeed, CCR7+ DCs injected in brain
tumors have been shown to migrate to the cervical lymph nodes
(CLNs) (Dunn et al., 2007; Fujita et al., 2009). Likewise, CCR7+
CD11c+ cells resembling classical bone marrow-derived DCs
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appear to be involved in other diseases such as CNS infectious
and autoimmune encephalitis (Ganguly et al., 2013).
CXCR3-CXCL10 Axis for T Lymphocytes
CXCR3 is a chemokine receptor that is rapidly induced on
naïve T lymphocyte following activation and preferentially
remains highly expressed on type-1 helper (Th1)-type CD4+
T lymphocytes, effector CD8+ T lymphocytes and innate-type
lymphocytes such as natural killer (NK) and NKT cells (Groom
and Luster, 2011). CXCR3 is activated by three interferon (IFN)-
γ-inducible ligands CXCL9, CXCL10, and CXCL11. Among these
chemokines, CXCL10 is induced by a variety of innate stimuli
that induce IFN-α/β as well as the adaptive immune cell cytokine
IFN-γ. CXCL10 has been attributed to several roles, such as (1)
chemoattraction for monocytes/macrophages, T lymphocytes,
NK cells, and dendritic cells; (2) promotion of T cell adhesion
to endothelial cells; and (3) inhibition of bone marrow colony
formation and angiogenesis.
In particular, Tc1 are known to efficiently traffic to the
CNS tumor site through CXCR3-CCL10 axis compared with
Tc2 (Nishimura et al., 2006; Zhu et al., 2007; Fujita et al.,
2009). CXCR3 is uniquely up-regulated on Tc1, which is critical
for efficient CNS tumor-homing of Tc1. Further information
on mechanisms underlying efficient CNS-tumor homing of
CTLs should be gained for development of truly effective
immunotherapy strategies for CNS tumors.
CCR2-CCL2 Axis for Macrophages/Microglia
CCR2 is a chemokine receptor, which regulates the mobilization
of monocytes from bone marrow to the inflammatory sites, and
it has been extensively studied in CNS inflammation (Chu et al.,
2014). CCR2 is activated by several chemokines, including CCL2,
CCL7, CCL8, CCL12, CCL13, and CCL16. Activation of CCR2
results in directional migration of receptor-bearing cell types.
Among them, CCL2 is known to be the most potent activator
of CCR2 signaling, leading to monocyte transmigration. In the
CNS tumor setting, CCL2 is secreted by tumor cells (Zhu et al.,
2011). CCL2 can directly promote angiogenesis through the
recruitment of tumor-associated macrophages (Salcedo et al.,
2000). In addition, CCL2 has been shown to be critical for cell
proliferation of CNS tumors, cancer cell metastasis, as well as
tumor aggressiveness (Huang et al., 2007).
In the CNS, macrophages/microglial cells constitute the first
line of cellular defense against a variety of stressors, participating
in the regulation of innate and adaptive immune responses
(Badie and Schartner, 2000). Many CNS tumors exhibit a
prominent macrophage/microglia infiltrate. It is postulated
that defense functions of macrophage/microglia against
glioma are compromised in the tumor microenvironment.
CNS macrophages/microglial cells expressed substantial
levels of CCR2 and Toll-like receptors (TLRs), which are
critical components for APCs to mediate innate immune
responses to any infectious or traumatic challenge and
activating adaptive immune responses. However, CNS
macrophages/microglial cells do not appear to produce
pro-inflammatory cytokines such as TNF-α, IL-1, or IL-6.
Moreover, these cells, in addition to decreased surface expression
of MHC class II (Watters et al., 2005), lack expression of the
costimulatory molecules CD86, CD80, and CD40 critical for
T cell activation, thereby unable to activate T cells properly
ex vivo (Hussain et al., 2006). Therefore, in the CNS tumor
microenvironment, macrophages/microglial cells are considered
to be immunosuppressive so that they are potent therapeutic
target for anti-CNS tumor immunotherapy (Fujita et al., 2010,
2011; Zhu et al., 2011).
CCR4-CCL22 Axis for Regulatory T Lymphocytes
(Tregs)
CD4+CD25+FoxP3+ Tregs are also found in the tumor
microenvironment (Zou, 2006). There are four potential sources
for Tregs in the CNS tumor microenvironment: the thymus,
lymph nodes, bone marrow, and peripheral blood traffic to the
tumor. Tregs express CCR4; abundant expression of CCL22, the
ligand for CCR4, in the tumor microenvironment stimulates
the tumor infiltration of Tregs. The tumor microenvironment
contains molecules that can suppress APC differentiation and
function. These dysfunctional APCs can in turn stimulate Treg
differentiation. In addition, DCs can stimulate Treg expansion,
and it is predicted that DCs in the tumor microenvironment
move toward draining lymph nodes and further induce Treg
expansion.
Similarly, the suppressive activity of Tregs is an important
factor since they limit CTL-mediated destruction of CNS tumor
cells. An increased ratio of CCR4+FoxP3+ Tregs to total
CD4+ T cells correlates with impairment of CD4+ T cell
proliferation in peripheral blood specimens obtained from CNS
tumor patients (Fecci et al., 2006; Hussain et al., 2006). Moreover,
Tregs are not present in normal brain tissue but are very
rarely found in low-grade gliomas and oligodendrogliomas
(Fujita et al., 2008; Heimberger et al., 2008). These studies
also observed that Tregs infiltration differs significantly in the
tumors according to lineage, pathology, and grade. In addition,
treatment of CNS tumor-bearing hosts with anti-CD25mAb
delayed the tumor growth and prolonged the survival, suggesting
that CCR4+CD4+CD25+ Tregs play an important role in
suppressing the immune response to CNS tumors (El Andaloussi
et al., 2006).
Perspectives
We reviewed recent progress in the field of the CNS and CNS
tumor immunology from a viewpoint of cell adhesion (primarily
integrins) and migration (primarily chemokines). As discussed
above, a line of studies have uncovered important roles of cell
adhesion and migration during development of multicellular
organisms as well as pathological conditions such as cancers.
In addition, kinetics of cell adhesion and migration in the CNS
provides a diverse scope for therapeutic strategies and target
molecules. Moreover, it is clear that the CNS and CNS tumors
are equipped with numerous layers of immunosuppression and
immune escape mechanisms, perhaps including ones that we
have not yet identified. These discoveries would allow us to
develop strategies to overcome each of these mechanisms. The
eventual success of tumor immunotherapies including those for
CNS tumors will be dependent upon not only implementation
of molecularly targeted trials that address multiple layers of
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challenges but also in-depth understanding of organ/tumor-
specific immunology mediated by organ-specific cell adhesion
and migration.
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